GUMM - Eliminate the Common Cold Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Street Walker who started this subject	5/8/2003 1:09:43 AM
From: StockDung	of 5582

EBI Securities, Inc. Reiterates Its Strong Buy Rating of Imclone Systems, Inc. Author/s: Issue: Oct 8, 1999 DENVER, Oct. 8 /PRNewswire/ -- The following is being issued by EBI Securities Corp., a member of the National Association of Securities Dealers, CRD Number 16184: EBI Securities, Inc. reiterates its Strong Buy Rating of Imclone Systems, Inc. (Nasdaq: IMCL). In his Research Update, EBI analyst David Lavigne stated that his view is that assessments concerning a Genentech patent's applicability to C225 are largely overblown. Lavigne noted that his greater concern was whether or not the current turmoil in the stock would affect IMCL's recently announced secondary. Lavigne also added that he continues to believe that successful results from current C225 clinical trials could significantly enhance the price of IMCL shares, especially from recently depressed levels. COPYRIGHT 1999 PR Newswire Association, Inc. COPYRIGHT 2000 Gale Group

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next